CNS Pharmaceuticals Pricing Update: Registered Direct Offering and Private Placement

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Private Placement

CNS Pharmaceuticals has recently concluded a significant financial move by initiating a registered direct offering and private placement, securing a substantial sum of $1.98 million. The achieved funds are aimed at fortifying the company's working capital and addressing general operational requirements.

• Key Points:
1. CNS Pharmaceuticals finalized a fundraising effort through a registered direct offering and private placement, generating $1.98 million.
2. The funds acquired will be allocated towards strengthening working capital and supporting general operational needs.
• Conclusion:

This financial maneuver marks a crucial step for CNS Pharmaceuticals, positioning the company for expanded growth and strategic advancement in its operational landscape.